{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T17:09:56Z","timestamp":1769879396035,"version":"3.49.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.msard.2023.104677","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T12:05:46Z","timestamp":1679918746000},"page":"104677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Longitudinal assessment of neurocognitive function in people with relapsing multiple sclerosis initiating alemtuzumab in routine clinical practice: LEM-COG study results"],"prefix":"10.1016","volume":"73","author":[{"given":"Jeffrey","family":"Wilken","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Traboulsee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Ionete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon","family":"Kolind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Fratto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Kane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roopali","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreea M.","family":"Rawlings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora","family":"Roesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Ozog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"DeLuca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.104677_bib0001","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1007\/s10072-020-04320-w","article-title":"Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosis","volume":"41","author":"Amato","year":"2020","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2023.104677_bib0002","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1037\/a0027890","article-title":"Comparison of the psychometric properties of two fatigue scales in multiple sclerosis","volume":"57","author":"Amtmann","year":"2012","journal-title":"Rehabil. Psychol."},{"key":"10.1016\/j.msard.2023.104677_bib0003","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1212\/WNL.0000000000003169","article-title":"Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon \u03b2-1a in MS","volume":"87","author":"Arnold","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104677_bib0004","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1177\/1352458519849796","article-title":"Impact of alemtuzumab on health-related quality of life over 6\u2009years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis","volume":"26","author":"Arroyo","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104677_bib0005","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00019052-200206000-00003","article-title":"The clinico-radiological paradox in multiple sclerosis revisited","volume":"15","author":"Barkhof","year":"2002","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2023.104677_bib0006","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1076\/clin.16.3.381.13859","article-title":"Minimal neuropsychological assessment of MS patients: a consensus approach","volume":"16","author":"Benedict","year":"2002","journal-title":"Clin. Neuropsychol."},{"key":"10.1016\/j.msard.2023.104677_bib0007","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1037\/1040-3590.8.2.145","article-title":"Revision of the Brief Visuospatial Memory Test: studies of normal performance, reliability, and validity","volume":"8","author":"Benedict","year":"1996","journal-title":"Psychol. Assess."},{"key":"10.1016\/j.msard.2023.104677_bib0009","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S1474-4422(20)30277-5","article-title":"Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues","volume":"19","author":"Benedict","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104677_bib0010","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/1352458517690821","article-title":"Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis","volume":"23","author":"Benedict","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104677_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103780","article-title":"Real-life evidence of treatment with alemtuzumab in patients diagnosed with relapsing-remitting multiple sclerosis in Colombia","volume":"61","author":"B\u00f3nitto","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104677_bib0012","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1007\/s10072-021-05145-x","article-title":"Effectiveness and safety of alemtuzumab in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational study","volume":"42","author":"Brecl Jakob","year":"2021","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2023.104677_bib0013","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1212\/WNL.24.11.1019","article-title":"Evaluating storage, retention, and retrieval in disordered memory and learning","volume":"24","author":"Buschke","year":"1974","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104677_bib0015","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1007\/s10072-020-04838-z","article-title":"Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results","volume":"42","author":"Capra","year":"2021","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2023.104677_bib0016","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s40263-020-00734-4","article-title":"Cognitive efficacy of pharmacologic treatments in multiple sclerosis: a systematic review","volume":"34","author":"Chen","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2023.104677_bib0017","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S1474-4422(08)70259-X","article-title":"Cognitive impairment in multiple sclerosis","volume":"7","author":"Chiaravalloti","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104677_bib0018","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2023.104677_bib0019","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","article-title":"Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings","volume":"89","author":"Coles","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104677_bib0020","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"Coles","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2023.104677_bib0021","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0b013e31824e8ee7","article-title":"Alemtuzumab more effective than interferon \u03b2-1a at 5-year follow-up of CAMMS223 clinical trial","volume":"78","author":"Coles","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104677_bib0022","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2023.104677_bib0023","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1002\/eji.200535075","article-title":"Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis","volume":"35","author":"Cox","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.msard.2023.104677_bib0024","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1212\/NXI.0000000000000194","article-title":"Alemtuzumab long-term immunologic effect: treg suppressor function increases up to 24 months","volume":"3","author":"De Mercanti","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2023.104677_bib0025","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1080\/13803390490496641","article-title":"Is speed of processing or working memory the primary information processing deficit in multiple sclerosis?","volume":"26","author":"Deluca","year":"2004","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"10.1016\/j.msard.2023.104677_bib0026","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41582-020-0355-1","article-title":"Treatment and management of cognitive dysfunction in patients with multiple sclerosis","volume":"16","author":"Deluca","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2023.104677_bib0027","article-title":"Effect of ozanimod on symbol digit modalities test performance in relapsing MS","volume":"48","author":"Deluca","year":"2021","journal-title":"Mul.t Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104677_bib0028","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nn.4528","article-title":"Regulatory T cells promote myelin regeneration in the central nervous system","volume":"20","author":"Dombrowski","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.msard.2023.104677_bib0029","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0165-0327(99)00156-1","article-title":"Discrepancies between self and observer ratings of depression. The relationship to demographic, clinical and personality variables","volume":"60","author":"Enns","year":"2000","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.msard.2023.104677_bib0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jns.2014.03.009","article-title":"Reliability of a cognitive endpoint for use in a multiple sclerosis pharmaceutical trial","volume":"340","author":"Erlanger","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2023.104677_bib0031","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.msard.2023.104677_bib0032","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/1531-8249(200012)48:6<885::AID-ANA9>3.0.CO;2-1","article-title":"Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group","volume":"48","author":"Fischer","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2023.104677_bib0033","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1017\/S0317167100048691","article-title":"The impact of fatigue on patients with multiple sclerosis","volume":"21","author":"Fisk","year":"1994","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.msard.2023.104677_bib0034","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1468-1331.2011.03507.x","article-title":"A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis","volume":"19","author":"Fox","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2023.104677_bib0035","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00415-019-09272-6","article-title":"Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis","volume":"266","author":"Frau","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.104677_bib0036","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1017\/S2045796019000088","article-title":"Translating the BDI and BDI-II into the HAMD and vice versa with equipercentile linking","volume":"29","author":"Furukawa","year":"2019","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"10.1016\/j.msard.2023.104677_bib0037","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1212\/WNL.0000000000003319","article-title":"Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients","volume":"87","author":"Giovannoni","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104677_bib0038","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/1756285610385608","article-title":"Evolving expectations around early management of multiple sclerosis","volume":"3","author":"Gold","year":"2010","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2023.104677_bib0039","first-page":"266","article-title":"The free and cued selective reminding test: evidence of psychometric adequacy","volume":"51","author":"Grober","year":"2009","journal-title":"Psychol. Sci. Q."},{"key":"10.1016\/j.msard.2023.104677_bib0040","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2023.104677_bib0041","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1177\/13524585211033190","article-title":"Paradigm shifts: early initiation of high-efficacy disease-modifying treatment in multiple sclerosis","volume":"27","author":"Hartung","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104677_bib0042","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/imm.12178","article-title":"Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro","volume":"141","author":"Havari","year":"2014","journal-title":"Immunology"},{"key":"10.1016\/j.msard.2023.104677_bib0043","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.0000000000004313","article-title":"Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy","volume":"89","author":"Havrdova","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104677_bib0044","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1756285614563522","article-title":"Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use","volume":"8","author":"Havrdova","year":"2015","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2023.104677_bib0045","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-2567.2009.03115.x","article-title":"Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model","volume":"128","author":"Hu","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.msard.2023.104677_bib0046","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-022-11134-7","article-title":"Objectively assessed physiological, physical, and cognitive function along with patient-reported outcomes during the first 2 years of Alemtuzumab treatment in multiple sclerosis: a prospective observational study","author":"Hvid","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.104677_bib0047","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.neubiorev.2017.09.005","article-title":"Distinct cognitive impairments in different disease courses of multiple sclerosis-A systematic review and meta-analysis","volume":"83","author":"Johnen","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.msard.2023.104677_bib0048","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1093\/brain\/awq176","article-title":"Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity","volume":"133","author":"Jones","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.msard.2023.104677_bib0049","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00415-015-7978-y","article-title":"Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis","volume":"263","author":"Kappos","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.104677_bib0051","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1212\/WNL.55.7.934","article-title":"Fatigue and declines in cognitive functioning in multiple sclerosis","volume":"55","author":"Krupp","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104677_bib0052","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/jnnp.59.1.77","article-title":"Attention related performance in two cognitively different subgroups of patients with multiple sclerosis","volume":"59","author":"Kujala","year":"1995","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2023.104677_bib0053","doi-asserted-by":"crossref","first-page":"e2373","DOI":"10.1212\/WNL.0000000000009522","article-title":"Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: a meta-analysis","volume":"94","author":"Landmeyer","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104677_bib0054","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1007\/s10072-020-04367-9","article-title":"A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting","volume":"41","author":"Lanzillo","year":"2020","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2023.104677_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102826","article-title":"Disease modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis","volume":"20","author":"Liu","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2023.104677_bib0059","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/arclin\/acaa028","article-title":"Symbol Digit Modalities Test: Greek normative data for the oral and written version and discriminative validity in patients with multiple sclerosis","volume":"36","author":"Messinis","year":"2021","journal-title":"Arch. Clin. Neuropsychol."},{"key":"10.1016\/j.msard.2023.104677_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.rehab.2021.101529","article-title":"Effective rehabilitation interventions and participation among people with multiple sclerosis: an overview of reviews","volume":"65","author":"Momsen","year":"2022","journal-title":"Ann. Phys. Rehabil. Med."},{"key":"10.1016\/j.msard.2023.104677_bib0063","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/135248506ms1227oa","article-title":"Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis","volume":"12","author":"Nocentini","year":"2006","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104677_bib0064","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.44.1.16","article-title":"The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial","volume":"44","author":"Noseworthy","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104677_bib0065","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s13311-017-0571-6","article-title":"Evolution of patient-reported outcomes and their role in multiple sclerosis clinical trials","volume":"14","author":"Nowinski","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2023.104677_bib0067","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s13311-019-00781-w","article-title":"Effects of natalizumab and fingolimod on clinical, cognitive, and magnetic resonance imaging measures in Multiple Sclerosis","volume":"17","author":"Preziosa","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2023.104677_bib0068","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1007\/s00415-018-9070-x","article-title":"No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study","volume":"265","author":"Prosperini","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.104677_bib0069","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104677_bib0070","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s11136-015-0940-8","article-title":"Psychometric properties of the Hamilton Depression Rating Scale in multiple sclerosis","volume":"24","author":"Raimo","year":"2015","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.msard.2023.104677_bib0071","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple Sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2023.104677_bib0072","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fneur.2017.00730","article-title":"Alemtuzumab improves cognitive processing speed in active multiple sclerosis-a longitudinal observational study","volume":"8","author":"Riepl","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2023.104677_bib0073","article-title":"Alemtuzumab for multiple sclerosis","volume":"4","author":"Riera","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.msard.2023.104677_bib0074","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3233\/JRS-191029","article-title":"Alemtuzumab for relapsing multiple sclerosis in clinical practice: a four-year retrospective one-center study","volume":"31","author":"Rodr\u00edguez De Castro","year":"2020","journal-title":"Int. J. Risk Saf. Med."},{"key":"10.1016\/j.msard.2023.104677_bib0075","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40263-016-0319-6","article-title":"Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis","volume":"30","author":"Roy","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2023.104677_bib0076","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1177\/1352458516674367","article-title":"Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes","volume":"23","author":"Ruano","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104677_bib0077","doi-asserted-by":"crossref","first-page":"16414","DOI":"10.3390\/ijms160716414","article-title":"Alemtuzumab in Multiple Sclerosis: mechanism of action and beyond","volume":"16","author":"Ruck","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2023.104677_bib0078","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.psychres.2011.11.014","article-title":"Sensitivity to detect change and the correlation of clinical factors with the Hamilton Depression Rating Scale and the Beck Depression Inventory in depressed inpatients","volume":"198","author":"Schneibel","year":"2012","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.msard.2023.104677_bib0079","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s00415-009-5441-7","article-title":"Living with multiple sclerosis: longitudinal changes in employment and the importance of symptom management","volume":"257","author":"Simmons","year":"2010","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.104677_bib0080","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4300\/JGME-D-12-00156.1","article-title":"Using effect size-or why the P value is not enough","volume":"4","author":"Sullivan","year":"2012","journal-title":"J. Grad. Med. Educ."},{"key":"10.1016\/j.msard.2023.104677_bib0082","article-title":"Memory rehabilitation for people with multiple sclerosis","volume":"10","author":"Taylor","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.msard.2023.104677_bib0083","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrneurol.2016.188","article-title":"Treatment decisions in multiple sclerosis \u2014 Insights from real-world observational studies","volume":"13","author":"Trojano","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2023.104677_bib0084","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1136\/jnnp-2014-307721","article-title":"Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy","volume":"86","author":"Tuohy","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2023.104677_bib0085","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/ene.12463","article-title":"The Symbol Digit Modalities Test as sentinel test for cognitive impairment in multiple sclerosis","volume":"21","author":"Van Schependom","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2023.104677_bib0086","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1177\/1352458519881759","article-title":"Efficacy of alemtuzumab over 6\u2009years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: post hoc analysis of the CARE-MS studies","volume":"26","author":"Van Wijmeersch","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104677_bib0087","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/jim-2016-000339","article-title":"Update on disease-modifying therapies for multiple sclerosis","volume":"65","author":"Vargas","year":"2017","journal-title":"J. Investig. Med."},{"key":"10.1016\/j.msard.2023.104677_bib0088","doi-asserted-by":"crossref","first-page":"120","DOI":"10.7224\/1537-2073.2012-043","article-title":"Changes in fatigue and cognition in patients with relapsing forms of multiple sclerosis treated with natalizumab: the ENER-G Study","volume":"15","author":"Wilken","year":"2013","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.msard.2023.104677_bib0089","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1191\/1352458503ms893oa","article-title":"The utility of computerized neuropsychological assessment of cognitive dysfunction in patients with relapsing-remitting multiple sclerosis","volume":"9","author":"Wilken","year":"2003","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104677_bib0090","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/13524585211044672","article-title":"Benchmarks of meaningful improvement on neurocognitive tests in multiple sclerosis","volume":"28","author":"Wojcik","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104677_bib0091","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s40263-020-00749-x","article-title":"Efficacy and safety of alemtuzumab through 9 years of follow-up in patients with highly active disease: post hoc analysis of CARE-MS I and II patients in the TOPAZ extension study","volume":"34","author":"Ziemssen","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2023.104677_bib0092","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/1756285617722706","article-title":"Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world","volume":"10","author":"Ziemssen","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2023.104677_bib0093","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jad.2013.04.028","article-title":"Severity classification on the Hamilton Depression Rating Scale","volume":"150","author":"Zimmerman","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.msard.2023.104677_bib0095","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s13760-020-01375-6","article-title":"Efficacy and safety of alemtuzumab treatment in a real-world cohort of patients with multiple sclerosis","volume":"121","author":"Zmira","year":"2021","journal-title":"Acta Neurol. Belg."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823001815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823001815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:05:48Z","timestamp":1761901548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823001815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":84,"alternative-id":["S2211034823001815"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104677","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal assessment of neurocognitive function in people with relapsing multiple sclerosis initiating alemtuzumab in routine clinical practice: LEM-COG study results","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104677","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104677"}}